Finance

Lists
TENX:NASDAQ
Tenax Therapeutics Inc
$1.62
+0.62%
(+0.0100) 1D
$1.62
-0.01% (-0.00010)
After hours
Closed: Nov 13, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TENX...
Open
$1.62
High
$1.64
Low
$1.54
Mkt. cap
73.77M
Avg. vol.
1.83M
Volume
901.93K
52-wk high
$19.40
52-wk low
$1.31
EPS
-$1.39
Beta
0.99
Shares outstanding
45.54M
No. of employees
15
Open
$1.62
High
$1.64
Low
$1.54
Mkt. cap
73.77M
Avg. vol.
1.83M
Volume
901.93K
52-wk high
$19.40
52-wk low
$1.31
EPS
-$1.39
Beta
0.99
Shares outstanding
45.54M
No. of employees
15
News stories
From web sources and news partners
About Tenax Therapeutics Inc
CEOChris Giordano
Employees15
Founded1967
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitetenaxthera.com
Analyst ratings
Based on 7 analysts giving stock ratings to TENX in the past 3 months
Buy
Buy
5
Hold
2
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for TENX in the last 3 months.
Highest
Current $1.62
$35.00 (+2,060.49%)
Average
$12.40 (+665.43%)
Lowest
$4.00 (+146.91%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jonathan Aschoff
Roth MKM
Buy
Maintained
$5.00
+208.6%
11/06/2026
Angela Qian
Canaccord Genuity
Buy
Maintained
$4.00
+146.9%
11/06/2026
David Risinger
Leerink Partners
Buy
Maintained
$4.00
+146.9%
10/09/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$14.00
+764.2%
09/15/2026
Olivia Brayer
Cantor Fitzgerald
Buy
Maintained
$35.00
+2,060.5%
09/09/2026
Matt Phipps
William Blair
Hold
Maintained
-
-
08/31/2026
Seamus Fernandez
Guggenheim
Hold
Downgraded
-
-
08/31/2026
Gautam Chukka
Chardan Capital
Hold
Downgraded
$5.00
+208.6%
08/11/2026
Gaurav Maini
LifeSci Capital
Buy
Maintained
$5.00
+208.6%
08/10/2026
Gavin Clark-Gartner
Evercore ISI
Hold
Downgraded
$5.00
+208.6%
08/10/2026
Unknown Analyst
Canaccord Genuity
Buy
Initiated
$35.00
+2,060.5%
07/28/2026
Unknown Analyst
Chardan Capital
Buy
Initiated
$27.00
+1,566.7%
06/22/2026
Unknown Analyst
Roth MKM
Buy
Maintained
$30.00
+1,751.9%
03/11/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
10.54M
11.54M
12.85M
12.07M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.91M
5.03M
5.93M
5.66M
Operating expense
16.45M
16.57M
18.78M
17.73M
Total operating expenses
16.45M
16.57M
18.78M
17.73M
Operating income
-16.45M
-16.57M
-18.78M
-17.73M
Other non operating income
-9.00K
-4.00K
-
-12.00K
EBT including unusual items
-15.54M
-15.72M
-17.80M
-16.70M
EBT excluding unusual items
-15.54M
-15.72M
-17.80M
-16.70M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-15.54M
-15.72M
-17.80M
-16.70M
Net profit margin
-
-
-
-
Earnings per share
-0.38
-0.35
-0.35
-0.31
Interest and investment income
918.00K
861.00K
981.00K
1.04M
Interest expense
-
-
-
-
Net interest expenses
918.00K
861.00K
981.00K
1.04M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps